|1.||Smith, Charles D: 12 articles (12/2015 - 01/2011)|
|2.||Lynch, Kevin R: 8 articles (09/2014 - 11/2005)|
|3.||Bittman, Robert: 8 articles (09/2014 - 05/2004)|
|4.||Vescovo, Giorgio: 7 articles (08/2010 - 09/2002)|
|5.||Dalla Libera, Luciano: 7 articles (08/2010 - 09/2002)|
|6.||Pitson, Stuart M: 6 articles (03/2015 - 09/2010)|
|7.||Spiegel, Sarah: 6 articles (01/2013 - 11/2002)|
|8.||Kharel, Yugesh: 6 articles (11/2012 - 11/2005)|
|9.||Miyake, Sachiko: 6 articles (06/2007 - 01/2004)|
|10.||Yamamura, Takashi: 6 articles (06/2007 - 01/2004)|
10/01/2015 - "However, this drug has also been shown to inhibit other cancer-associated signal transduction pathways in part because of its structural similarity to sphingosine, and consequently shows efficacy as an anti-cancer agent both in vitro and in vivo. "
01/01/2014 - "Ceramide (Cer) and sphingosine (Sph) interfere with critical cellular functions relevant for cancer progression and cell survival. "
11/01/2013 - "These results indicate that tumor-supporting sphingolipid metabolites act by making cells softer, while the anti-cancer metabolite sphingosine partially reverses the decreased elasticity associated with cancer progression. "
08/21/2013 - "According to the results of a flow cytometric analysis, cancer cells fed with NBD-triyne-sphingosine showed significantly increased fluorescence intensity compared with the NBD-sphingosine treated cells. "
05/01/2013 - "Nevertheless, they are supported by the lately discovered tumor-suppressing function of sphingosine, the enzymatic product of AC."
09/01/2012 - "Hence, we investigated whether sphingosine and the structural analog fingolimod/FTY720, a recently introduced therapeutic for multiple sclerosis, affect (i) intracellular vesicle mobility and (ii) vesicle cargo discharge from cultured rat astrocytes. "
09/01/2010 - "Importantly, FTY720, a sphingosine analogue with apoptotic activity that is currently in phase III clinical trials for multiple sclerosis, acts in a similar manner to sphingosine in potentiating 14-3-3 phosphorylation. "
10/01/2015 - "Interestingly however fingolimod, an immunosuppressive drug structurally related to sphingosine, used for the treatment of multiple sclerosis, is a powerful activator of Fam20C, both wild type and its pathogenic, loss of function, T268M mutant. "
04/01/2015 - "Fingolimod, a structural analogue of sphingosine, is the first oral treatment available for multiple sclerosis. "
01/01/2015 - "FTY720 (fingolimod, Gilenya), a sphingosine analog, is the Food and Drug Administration (FDA)-approved prodrug for treatment of multiple sclerosis that also has anticancer actions that are not yet well understood. "
10/24/2008 - "Extending the time of ischemia further to 90min almost eliminated cardioprotection by S1P or sphingosine; and their combination gave only modest protection. "
01/01/2012 - "Sphingosine kinase-2 inhibition improves mitochondrial function and survival after hepatic ischemia-reperfusion."
12/01/2011 - "Ceramide (the key sphingolipid, a precursor of sphingosine) is claimed to be responsible for activation of apoptosis during ischemia/reperfusion. "
10/24/2008 - "Extending the ischemia to 75min reduced protection by both S1P and sphingosine, but protection could be enhanced by employing them in combination. "
03/01/2008 - "Consistent with previous reports, sphingosine at a high concentration (5 microM) was cardiotoxic as evidenced by increased infarct size in response to ischemia/reperfusion in an ex vivo rat heart. "
01/01/2012 - "This study investigated the roles of sphingosine kinase-2 (SK2) in inflammation after LT. "
01/01/2012 - "This study investigated the roles of sphingosine kinase-2 (SK2) in mitochondrial dysfunction and inflammation after hepatic IR. "
01/01/2015 - "Airway delivery of the non-phosphorylated sphingosine analog, but not its pre-phosphorylated counterpart, is highly efficient at controlling the local T cell response after the onset of allergic airway inflammation. "
04/01/2014 - "SK1 phosphorylates sphingosine to form sphingosine 1 phosphate (S1P), a bioactive sphingolipid with numerous roles in inflammation. "
09/01/2010 - "Sphingosine phosphate receptors are coupled to numerous different intracellular signaling cascades exerting roles in vasodilatation, inflammation, cell migration and apoptosis, inhibition of platelet activation, and endothelial adhesion molecule expression, among other functions. "
|5.||Squamous Cell Carcinoma (Epidermoid Carcinoma)
04/05/1990 - "Demonstration of its endogenous occurrence (and the virtual absence of unsubstituted sphingosine) in human epidermoid carcinoma A431 cells."
04/15/1988 - "The regulation of protein phosphorylation by sphingosine in A431 human epidermoid carcinoma cells was examined. "
04/15/1988 - "Regulation of the epidermal growth factor receptor phosphorylation state by sphingosine in A431 human epidermoid carcinoma cells."
01/01/2014 - "The aim of this study was to evaluate the anti-tumor efficacy of C2-ceramide (C2-Cer; N-acetyl-D-sphingosine) by investigating cell death and autophagy in head and neck squamous cell carcinoma (HNSCC) cells. "
12/01/2015 - "In an article associated with this dataset, Poulson and colleagues determined the cytotoxicities of long-chain bases (sphingosine, dihydrosphingosine, and phytosphingosine) for human oral gingival epithelial (GE) keratinocytes, oral gingival fibroblasts (GF), dendritic cells (DC), and squamous cell carcinoma (SCC) cell lines . "
|5.||sphingosine 1-phosphate (sphingosine-1-phosphate)
|3.||Heterologous Transplantation (Xenotransplantation)
|4.||Homologous Transplantation (Allograft)